Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos (t) ide analogues therapy
S Liu, R Deng, B Zhou, X Liang, Z Liu… - The Journal of …, 2022 - academic.oup.com
Background Whether serum hepatitis B virus (HBV) RNA associates with hepatocellular
carcinoma (HCC) development in chronic hepatitis B (CHB) patients has not been fully …
carcinoma (HCC) development in chronic hepatitis B (CHB) patients has not been fully …
Hepatitis B virus (HBV) core-related antigen during nucleos (t) ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular …
M Honda, T Shirasaki, T Terashima… - The Journal of …, 2016 - academic.oup.com
Background. Although nucleos (t) ide analog (NA) therapy effectively reduces the hepatitis B
virus (HBV) DNA load in the serum of patients with chronic hepatitis B, it does not completely …
virus (HBV) DNA load in the serum of patients with chronic hepatitis B, it does not completely …
Impact of hepatitis B core‐related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos (t) ide analogues
T Hosaka, F Suzuki, M Kobayashi… - Alimentary …, 2019 - Wiley Online Library
Background Chronic hepatitis B virus (HBV) infection is an aetiologic factor for
hepatocellular carcinoma (HCC). Baseline HBV DNA is a known independent predictor of …
hepatocellular carcinoma (HCC). Baseline HBV DNA is a known independent predictor of …
Effect of nucleos (t) ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis
T Kumada, H Toyoda, T Tada, S Kiriyama… - Journal of …, 2013 - Elsevier
BACKGROUND & AIMS: Some patients with chronic hepatitis B virus (HBV) infection
progress to hepatocellular carcinoma (HCC). However, the long-term effect of nucleos (t) ide …
progress to hepatocellular carcinoma (HCC). However, the long-term effect of nucleos (t) ide …
[HTML][HTML] Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound
J Wang, T Shen, X Huang, GR Kumar, X Chen… - Journal of …, 2016 - Elsevier
Background & Aims Hepatitis B virus (HBV) RNA in serum has recently been linked to
efficacy and prognosis of chronic hepatitis B (CHB) treatment. This study explored the …
efficacy and prognosis of chronic hepatitis B (CHB) treatment. This study explored the …
Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos (t) ide …
M Kawanaka, K Nishino, J Nakamura, T Oka, N Urata… - Liver cancer, 2014 - karger.com
Background: Serum levels of hepatitis B virus (HBV) DNA are an important predictor of the
risk of hepatocellular carcinoma (HCC) in patients with chronic HBV infection. However, little …
risk of hepatocellular carcinoma (HCC) in patients with chronic HBV infection. However, little …
[HTML][HTML] Levels of HBV RNA in chronic HBV infected patients during first-line nucleos (t) ide analogues therapy
B Jiang, Q Dai, Y Liu, G Yu, Y Mi - Infectious Agents and Cancer, 2022 - Springer
Abstract Background Serum HBV RNA has been considered a potential biomarker in
monitoring the prognosis of chronic hepatitis B (CHB). However, Real-life cohort studies on …
monitoring the prognosis of chronic hepatitis B (CHB). However, Real-life cohort studies on …
The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes …
ZQ Li, CL Hu, P Yu, XY Gu, JJ Zhang, H Li… - Clinics and Research in …, 2017 - Elsevier
Background Patients with chronic hepatitis B virus (HBV) infection are at high risk for
progressing to decompensated cirrhosis and hepatocellular carcinoma (HCC). Although …
progressing to decompensated cirrhosis and hepatocellular carcinoma (HCC). Although …
Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos (t) ide analogues
L Jansen, NA Kootstra, KA van Dort… - The Journal of …, 2016 - academic.oup.com
Background. Treatment of patients with chronic hepatitis B (CHB) with nucleos (t) ide
analogues (NAs) suppresses hepatitis B virus (HBV) DNA production but does not affect the …
analogues (NAs) suppresses hepatitis B virus (HBV) DNA production but does not affect the …
Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg‐positive chronic hepatitis B treated with nucleos (t) ide analogues
S Liu, Z Liu, W Li, B Zhou, X Liang… - Alimentary …, 2020 - Wiley Online Library
Background Serum hepatitis B virus (HBV) RNA is a novel biomarker for evaluating
treatment response. Detailed information regarding serum HBV RNA kinetics during …
treatment response. Detailed information regarding serum HBV RNA kinetics during …